Premium
Left Ventricular Hypertrophy and Antiarrhythmic Drugs in Atrial Fibrillation: Impact on Mortality
Author(s) -
CHUNG ROY,
HOUGHTALING PENNY L.,
TCHOU MICHAEL,
NIEBAUER MARK J.,
LINDSAY BRUCE D.,
TCHOU PATRICK J.,
CHUNG MINA K.
Publication year - 2014
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/pace.12426
Subject(s) - medicine , cardiology , amiodarone , ejection fraction , atrial fibrillation , left ventricular hypertrophy , cardioversion , heart failure , coronary artery disease , blood pressure
Background Despite sparse clinical data, current atrial fibrillation (AF) guidelines favor amiodarone as a drug of choice for patients with left ventricular hypertrophy (LVH). Objective This study tested the hypothesis that patients with persistent AF and LVH on nonamiodarone antiarrhythmics have higher mortality compared to patients on amiodarone. Methods In an observational cohort analysis of patients who underwent cardioversion for AF, patients with LVH, defined as left ventricular wall thickness ≥1.4 cm, by echocardiogram prior to their first cardioversion, were included; clinical data, including antiarrhythmic drugs and ejection fraction (LVEF), were collected. Mortality, determined via the Social Security Death Index, was analyzed using Kaplan‐Meier and Cox proportional hazards models to determine whether antiarrhythmic drugs were associated with higher mortality. Results In 3,926 patients, echocardiographic wall thickness was available in 1,399 (age 66.8 ± 11.8 years, 67% male, LVEF 46 ± 15%, septum 1.3 ± 0.4, posterior wall 1.2 ± 0.2 cm), and 537 (38%) had LVH ≥1.4 cm. Among 537 patients with LVH, mean age was 67.5 ± 11.7 years, 76.4% were males, and mean LVEF was 48.3 ± 13.3%. Amiodarone was associated with lower survival (log rank P = 0.001), including after adjusting for age, LVEF, and coronary artery disease (P = 0.023). In propensity‐score matched cohorts with LVH treated with no drugs, nonamiodarone antiarrhythmic drugs (non‐AADs), or amiodarone (N = 65 each group), there was early lower survival in patients on amiodarone (P = 0.05). Conclusions Patients with persistent AF and LVH on non‐AADs do not have higher mortality compared to patients on amiodarone. Importantly, these findings do not support amiodarone as a superior choice in patients with LVH.